CONTACT US
Home > Inhibitors/Agonists>CMV> > CMX001
444805-28-1-CMX001 CMX001

CMX001

  • CAT Number: I003575
  • CAS Number: 444805-28-1
  • Molecular Formula: C27H52N3O7P
  • Molecular Weight: 561.701
  • Purity: 98%
Inquiry Now

CMX001 (Cat No.:I003575) was developed as an orally active, lipophilic form of cidofovir (CDV); has enhanced activity in vitro and in vivo compared to CDV against certain herpesviruses, adenoviruses, and orthopoxviruses.CMX001 is currently in Phase II clinical studies for development as a therapeutic agent for human CMV, adenovirus, and BK virus infections, as well as, for adverse events following smallpox vaccinations.


Catalog Number I003575
CAS Number 444805-28-1
Synonyms

[(2S)-1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl]oxymethyl-(3-hexadecoxypropoxy)phosphinic acid

Molecular Formula C27H52N3O7P
Purity 98%
Target CMV
Solubility 10 mM in DMSO
Appearance Solid powder
Storage Store at -20C
IC50 5.5 nM (EC50, in PDA at 7 dpi) [3]
IUPAC Name [(2S)-1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl]oxymethyl-(3-hexadecoxypropoxy)phosphinic acid
InChI InChI=1S/C27H52N3O7P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-19-35-20-16-21-37-38(33,34)24-36-25(23-31)22-30-18-17-26(28)29-27(30)32/h17-18,25,31H,2-16,19-24H2,1H3,(H,33,34)(H2,28,29,32)/t25-/m0/s1
InChIKey WXJFKKQWPMNTIM-VWLOTQADSA-N
SMILES CCCCCCCCCCCCCCCCOCCCOP(=O)(COC(CN1C=CC(=NC1=O)N)CO)O
Reference

<br />
1:Brincidofovir (CMX001) inhibits BK polyomavirus replication in primary human urothelial cells. Tylden GD, Hirsch HH, Rinaldo CH.Antimicrob Agents Chemother. 2015;59(6):3306-16. doi: 10.1128/AAC.00238-15. Epub 2015 Mar 23. PMID: 25801568 Free PMC Article<br />
2:Treatment of BK virus-associated nephropathy with CMX001 after kidney transplantation in a young child. Reisman L, Habib S, McClure GB, Latiolais LS, Vanchiere JA.Pediatr Transplant. 2014 Nov;18(7):E227-31. doi: 10.1111/petr.12340. Epub 2014 Aug 30. PMID: 25174393<br />
3:Co-administration of the broad-spectrum antiviral, brincidofovir (CMX001), with smallpox vaccine does not compromise vaccine protection in mice challenged with ectromelia virus. Parker S, Crump R, Foster S, Hartzler H, Hembrador E, Lanier ER, Painter G, Schriewer J, Trost LC, Buller RM.Antiviral Res. 2014 Nov;111:42-52. doi: 10.1016/j.antiviral.2014.08.003. Epub 2014 Aug 13. PMID: 25128688<br />
4:Development of CMX001 (Brincidofovir) for the treatment of serious diseases or conditions caused by dsDNA viruses. Florescu DF, Keck MA.Expert Rev Anti Infect Ther. 2014 Oct;12(10):1171-8. doi: 10.1586/14787210.2014.948847. Epub 2014 Aug 13. PMID: 25120093<br />
5:CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. Marty FM, Winston DJ, Rowley SD, Vance E, Papanicolaou GA, Mullane KM, Brundage TM, Robertson AT, Godkin S, Momm&eacute;ja-Marin H, Boeckh M; CMX001-201 Clinical Study Group..N Engl J Med. 2013 Sep 26;369(13):1227-36. doi: 10.1056/NEJMoa1303688. PMID: 24066743 Free Article<br />
6:Selection and recombinant phenotyping of a novel CMX001 and cidofovir resistance mutation in human cytomegalovirus. James SH, Price NB, Hartline CB, Lanier ER, Prichard MN.Antimicrob Agents Chemother. 2013 Jul;57(7):3321-5. doi: 10.1128/AAC.00062-13. Epub 2013 May 6. PMID: 23650158 Free PMC Article<br />
7:Progressive vaccinia: case description and laboratory-guided therapy with vaccinia immune globulin, ST-246, and CMX001. Lederman ER, Davidson W, Groff HL, Smith SK, Warkentien T, Li Y, Wilkins KA, Karem KL, Akondy RS, Ahmed R, Frace M, Shieh WJ, Zaki S, Hruby DE, Painter WP, Bergman KL, Cohen JI, Damon IK.J Infect Dis. 2012 Nov;206(9):1372-85. doi: 10.1093/infdis/jis510. Epub 2012 Aug 16. PMID: 22904336 Free PMC Article<br />
8:First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broad-spectrum oral drug active against double-stranded DNA viruses. Painter W, Robertson A, Trost LC, Godkin S, Lampert B, Painter G.Antimicrob Agents Chemother. 2012 May;56(5):2726-34. doi: 10.1128/AAC.05983-11. Epub 2012 Mar 5. PMID: 22391537 Free PMC Article<br />
9:Treatment of Vaccinia and Cowpox Virus Infections in Mice with CMX001 and ST-246. Quenelle DC, Kern ER.Viruses. 2010 Dec;2(12):2681-95. doi: 10.3390/v2122681. Epub 2010 Dec 13. PMID: 21994637 Free PMC Article<br />
10:Safety and efficacy of CMX001 as salvage therapy for severe adenovirus infections in immunocompromised patients. Florescu DF, Pergam SA, Neely MN, Qiu F, Johnston C, Way S, Sande J, Lewinsohn DA, Guzman-Cottrill JA, Graham ML, Papanicolaou G, Kurtzberg J, Rigdon J, Painter W, Mommeja-Marin H, Lanier R, Anderson M, van der Horst C.Biol Blood Marrow Transplant. 2012 May;18(5):731-8. doi: 10.1016/j.bbmt.2011.09.007. Epub 2011 Sep 29. PMID: 21963623 Free PMC Article

Request a Quote